Evidence map›Paper›PMID 41502783›Full record

ArticleNano today2024

Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy.

Hsuan-Chen Liu, Nicola Di Trani, Marzia Conte, Dinh Chuong Nguyen, Simbarashe Jokonya, Abe Wu, Robin Vander Pol, Ashley L Joubert, Ilaria Facchi, Anthony M Wood and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano today, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hsuan-Chen LiuDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Nicola Di TraniDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Marzia ConteDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Dinh Chuong NguyenDepartment of Bioengineering and Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA, USA.
Simbarashe JokonyaDepartment of Bioengineering and Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA, USA.
Abe WuDepartment of Bioengineering and Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA, USA.
Robin Vander PolDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Ashley L JoubertDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Ilaria FacchiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Anthony M WoodDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Jeremy HoDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Federica PesaresiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Valentina CaudaDepartment of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi 24, Torino 10129, Italy.
Shu-Hsia ChenCenter for Immunotherapy Research, Houston Methodist Research Institute, Houston, Texas, USA.
Xuewu LiuDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Patrick S StaytonDepartment of Bioengineering and Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA, USA.
Corrine Ying Xuan ChuaDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Alessandro GrattoniDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Funding

Engineered Antimicrobial Platform to Target Pulmonary Intracellular InfectionsR01AI134729 · NIAID · UNIVERSITY OF WASHINGTON · PI Shawn J. Skerrett, Patrick S. Stayton · 2018 to 2026
$4.9M
Long-acting multi prevention implant for 2-year contraception and HIV PrEPR01AI167659 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Alessandro Grattoni, Patrick S. Stayton · 2023 to 2026
$3.3M
An integrated polymeric carrier for subunit cancer vaccinesR01CA257563 · NCI · UNIVERSITY OF WASHINGTON · PI PUN, SUZIE H., STAYTON, PATRICK S. · 2021 to 2025
$2.4M
A nanofluidic platform for tunable drug deliveryR01GM127558 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GRATTONI, ALESSANDRO, LIU, XUEWU · 2018 to 2021
$1.6M
NCI NIH HHS R01 CA257563NIAID NIH HHS R01 AI134729NIAID NIH HHS R01 AI167659NIGMS NIH HHS R01 GM127558
6 · The paper itself

Abstract

Intratumoral immunotherapy holds promise for improving cancer treatment efficacy. However, rapid clearance from the tumor upon bolus volume injections limits efficacy and impedes assessment of dose-dependent effects on the tumor immune microenvironment (TIME). To this end, we developed a drug-agnostic nanofluidic implant to deliver immunotherapy within the tumor, providing a mechanism for sustained and controlled intratumoral dosing. Diffusive drug elution from the implant reservoir is controlled by a nanofluidic membrane, which abrogates rapid drug elimination from the tumor and maximizes immunotherapy localization. Here we first achieve

Indexed as

Controlled releaseDrug deliveryImmune checkpoint inhibitorsIntratumoral immunotherapyNanofluidic implantSTING agonistToll-like receptor agonist

Identifiers

PMID41502783
PMCPMC12774477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.